Board of Directors

John M. Abrahams, MD

President of Brain and Spine Surgeons of New York a practicing neurosurgeon at three NYC area hospitals.   He is Associate Professor of Neurological Surgery at New York Medical College at Westchester Medical Center, a Level 1 Trauma Center.  He is also Assistant Professor at Albert Einstein College of Medicine, Montefiore Medical center. Within the practice of neurosurgery, Dr. Abrahams has a focus on intracranial surgery and brain tumors. He is the founder of the Westchester Neuroscience Research Foundation to research malignant brain tumors, stroke and spinal cord injuries, and is a co-founder of Endomedix.

Weiliam Chen, Ph.D., RPh.

20 years of research experience in both university-based research centers and associated private research groups. He previously held academic appointments at the University of Michigan Medical School, University of Pennsylvania School of Medicine/Children’s Hospital of Philadelphia, SUNY-Stony Brook Department of Biomedical Engineering, and New York University School of Medicine. In addition to co-founding Endomedix,  Dr. Chen is a co-founder of Sustained Nano Systems, a firm using nanovector and microvector components to enhance drug delivery. Dr. Chen is the Principal Investigator for the 7 NIH-funded SBIR grants awarded to date to Endomedix, with a total value of $2.8 million. Dr. Chen  also serves on many national and international grant review panels including the National Institutes of  Health, the Department of Defense, the Science Foundation of Ireland, UK Medical Research Council, Israel Science foundation, and Portugal Fundacao para a Ciencia e a Tecnologia.

Anthony D’Ambrosio, MD, MBA

Anthony D’Ambrosio, MD, MBA is a Clinical Assistant Professor at Department of Neurosurgery at NYU Grossman School of Medicine and is also President of Neurosurgeons of New Jersey.   Though his practice includes treatment of spial disorders, Dr. D’Ambrosio is particularly active in performing craniotomies for the removal of brain tumors and also manages metastatic brain tumors.  He also performs Gamma Knife radiosurgery, in which highly precise radiation therapy is used to destroy tumors.  Dr. D’Ambrosio earned a BS biology at University of North Carolina at Chapel Hill and a Doctor of Medicine at Vanderbilt School of Medicine.  He completed his neurosurgery residency at Columbia University Vagelos College of Physicians and Surgeons and a fellowship of Skull Base Neurosurgery at University of South Florida.  He subsequently earned a MBA at UNC Kenan-Flagler Business School.

Richard Olson

A veteran of the pharmaceutical and consumer health sectors. He served as Vice President of Richardson-Vicks in the Vick Americas/Far East Division and in the Vick Health Care Division. Dick later served as Executive Vice President Fisons Consumer Health USA and as Vice President of Business Development for Schering-Plough Healthcare Products. He has been an advisor and consultant to several early stage companies in the analgesics, diagnostics and women’s health sectors. Dick earned a BSc in Industrial and Labor Relations and also an MBA, both at Cornell University.

James R Pastena

A medical device executive with 35+ years in the orthopaedic and spinal/ neurosurgical sectors. Jim has been president of EBI Medical Systems division of Biomet, a $550 M business unit focused on bine growth stimulation and spinal implant devices, and afterward become president of Precision Spine, a privately held spinal implant device firm.  He is also a board member of Paradigm Spine LLC.  Jim is a graduate of Farleigh Dickinson University.

Richard Russo

Richard is a member of the Board and functions as its Chair. Richard Russo is a MedTech veteran, with a history of success in both major corporations and early ventures. He held sales, product management and marketing, and business development positions at American Hospital Supply Corporation, American Sterilizer Company, Electro-Biology, Inc. and C.R, Bard, Inc. He joined Osteotech, Inc. as Director of Business Development and Regulatory Affairs. He had several notable accomplishments there. He successfully led the designation of the Company’s major product as a human tissue not requiring FDA premarket clearance after the Agency had initially designated it as a combination product, Class III medical device and biological drug. He established the marketing direction for the lead product, and led the acquisition of a failing French firm and the establishment of a Bulgarian subsidiary and led the European operation as president to become the leading tissue products company globally.

At Endomedix , Richard led the corporate pivot to a new business model, changed product development targets, and rescued a failing R&D program through the establishment of a new R&D team and lab. He negotiated a successful exit of a unfavorable product and technology license to Integra Life Sciences, relieved the legal founders of their operational roles, and redirected a failed patent program. Since the operational restart of the Company in 2014, before the successful development of the Company’s technology and first product, he stepped in to become Endomedix’s lead cash investor. Richard earned a BA in philosophy from Boston College and a MBA from Columbia University.

Marsha Wender Timmerman

Marsha Wender Timmerman is a Partner and founder of AJM Investments, LLC,  Prior to founding  AJM, Marsha was a board member and leader in the development team of Biocoat, Inc., a venture developing and supplying hydrophilic coatings for medical device applications that was acquired by 1315 Capital. Prior to Biocoat, Marsha was Co-Founder and President of JWT, Inc., a developer of diagnostic kits that merged with Binax Services. Marsha had lead product development roles at ImmunaCare Corp., Enzymatics and Air Products and Chemicals. Marsha earned a BS in Zoology at Michigan State University and a MS in Biology at Rutgers University.